Lower brain glucose levels found in people with obesity, type 2 diabetes
Glucose levels are reduced in the brains of individuals with obesity and type 2 diabetes compared to lean individuals, according to a new Yale study. The finding might explain disordered eating behavior — and even a higher risk of Alzheimer’s disease — among obese and diabetic individuals, the researchers said.
How leptin, the ‘satiety hormone,’ reverses diabetes
Treatment with leptin, the hormone associated with fullness or satiety, reverses hyperglycemia in animals models of poorly controlled type 1 (T1D) and type 2 (T2D) diabetes by suppressing the neuroendocrine pathways that cause blood glucose levels to soar, a Yale-led team of researchers has found. The study appears in the Advance Online Publication of Nature Medicine.
Herold is New Chair of International Diabetes Consortium
Kevan C. Herold, MD, C.N.H. Long Professor of Immunobiology and professor of medicine (endocrinology) at Yale School of Medicine, has been named chair of Type 1 Diabetes (T1D) TrialNet, an international consortium dedicated to finding ways to prevent, delay, and slow progression of the disease.
Conn. Health Providers Say Drug Maker Restrictions On Discount Program Will Leave Patients Stranded
The 340B Drug Pricing Program was created as a safety net to help uninsured and low-income patients afford medications. It requires drug manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to hospitals, community health centers, clinics and other eligible health sites.Source: WNPR
Pandemic Creates Greater Financial, Physical And Mental Burdens On Conn. Diabetics
Managing a lifetime disease like diabetes often comes with a high price tag and can take a toll on someone’s mental health. Connecticut advocates and providers said adding in a global pandemic has left patients dealing with an even heavier burden of financial, physical and mental health needs.Source: WNPR